Low-Dose THC Plus an Anti-Inflammatory Drug Shows Promise for Alzheimer's Prevention
Combining low-dose THC with celecoxib (a COX-2 inhibitor) reduced both amyloid and tau pathology in Alzheimer's mice and improved cognitive function more than either drug alone.
Quick Facts
What This Study Found
THC (3.0 mg/kg) alone or with celecoxib (1.0 mg/kg) reduced amyloid-beta and tau pathology, enhanced synaptic markers, and prevented cognitive decline. The combination produced greater improvements in spatial learning and mitigated THC-induced neuroinflammation. Both drugs are already FDA-approved.
Key Numbers
THC 3.0 mg/kg + celecoxib 1.0 mg/kg. Reduced Aβ and tau pathologies. Enhanced synaptic marker expression. Combination improved spatial learning more than THC alone. Gene expression changes reversed AD-associated patterns.
How They Did This
Preclinical study treating Alzheimer's model mice with low-dose THC alone or combined with celecoxib, measuring amyloid/tau pathology, synaptic markers, cognitive function, neuroinflammation, and gene expression changes.
Why This Research Matters
Both THC (as dronabinol/nabilone) and celecoxib are already FDA-approved, meaning this combination could potentially advance to clinical trials rapidly if preclinical results hold up — a rare advantage in Alzheimer's drug development.
The Bigger Picture
Alzheimer's treatment has seen decades of failures. The strategy of combining an existing cannabinoid with an anti-inflammatory to counter THC's own inflammatory effects while leveraging its neuroprotective properties is an elegant repurposing approach.
What This Study Doesn't Tell Us
Mouse model doesn't fully replicate human AD. THC dose translation to humans is uncertain. Long-term safety of the combination is unknown. Single AD model tested.
Questions This Raises
- ?Could this combination prevent AD onset in high-risk individuals?
- ?Would the combination's cognitive benefits translate to human patients with existing dementia?
Trust & Context
- Key Stat:
- Evidence Grade:
- Comprehensive preclinical study with gene expression and behavioral endpoints. The use of already-approved drugs strengthens translational relevance.
- Study Age:
- Recent study proposing a novel combination strategy using existing FDA-approved medications for Alzheimer's prevention.
- Original Title:
- A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease.
- Published In:
- Aging and disease (2025)
- Authors:
- Zhang, Jian(3), Zhu, Dexiao, Hu, Mei, Pan, Mingzhe, Chen, Chu
- Database ID:
- RTHC-08033
Evidence Hierarchy
Frequently Asked Questions
Could THC treat Alzheimer's disease?
Low-dose THC showed benefits in this mouse study, but combining it with celecoxib was even better — the anti-inflammatory countered THC's own inflammatory effects while both drugs attacked Alzheimer's pathology from different angles.
Why combine THC with an anti-inflammatory?
THC has neuroprotective effects but also induces some neuroinflammation via COX-2. Adding celecoxib (a COX-2 inhibitor) blocks the unwanted inflammation while preserving THC's benefits, creating a net positive effect.
Read More on RethinkTHC
- THC-purity-potency-label-meaning
- dab-concentrate-addiction-withdrawal
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- healthiest-way-to-consume-cannabis
- how-cannabis-products-made-concentrates-edibles
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- sativa-vs-indica-difference-myth
- weed-potency-withdrawal
Cite This Study
https://rethinkthc.com/research/RTHC-08033APA
Zhang, Jian; Zhu, Dexiao; Hu, Mei; Pan, Mingzhe; Chen, Chu. (2025). A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease.. Aging and disease. https://doi.org/10.14336/AD.2025.1206
MLA
Zhang, Jian, et al. "A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease.." Aging and disease, 2025. https://doi.org/10.14336/AD.2025.1206
RethinkTHC
RethinkTHC Research Database. "A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeu..." RTHC-08033. Retrieved from https://rethinkthc.com/research/zhang-2025-a-combination-of-lowdose
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.